Widely hailed as the next frontier in medical advances, the promise of individualized medicine is becoming a reality thanks to progress in understanding the molecular basis of diseases such as breast cancer. Scientists can now develop treatments that are tailored to individual genetic profiles, as well as tests to predict how a patient will respond to existing therapies. Today, some women with early-stage breast cancer and their physicians can make more informed treatment decisions with the Oncotype DX Breast Cancer Assay. This service provides quantitative information about genes from a woman’s individual tumor to generate a Recurrence Score between zero and 100, indicating whether she is at high, intermediate or low risk for her cancer returning after treatment. Oncotype DX is intended for patients with node-negative, estrogen receptor-positive breast cancer who are likely to be treated with hormonal therapy. Approximately half of the 230,000 patients diagnosed with breast cancer in the United States each year fall into this category, and are frequently offered treatment with chemotherapy, a widely used treatment with considerable side effects. Clinical studies show that chemotherapy improved patient survival rates in only 4 out of 100 patients, yet thousands of women continue to elect this costly and toxic treatment with only limited information about whether they might respond to it. A recent study demonstrated that women with high Recurrence Scores are more likely to benefit from chemotherapy, whereas women with lower scores derive only minimal benefit. Further, only 25% of women fell into the high-risk group, compared to 50% in the low-risk group, indicating that this common treatment is not appropriate for every patient. Elizabeth Sloan of New York City is one of the many breast cancer patients not likely to respond to chemotherapy. An active mother with two young boys, Elizabeth was considering having another child when she was diagnosed at just 40 years old. She wanted to avoid chemotherapy, with its disruptive, short-term side effects and potentially serious long-term implications, but also wanted to be absolutely certain that it wouldn’t help her. Working with her doctor, Ruth Oratz, M.D., at NYU Medical Center, Elizabeth decided to have the Oncotype DX assay, and was delighted when her Recurrence Score turned out to be low-indicating that she may not benefit significantly from chemotherapy. “No two women with breast cancer are exactly alike. Oncotype DX provides information that goes beyond standard measures, like age, tumor size and tumor grade, in determining the likelihood of disease recurrence,” says Dr. Oratz. “Oncotype DX gave Elizabeth and me added confidence and peace of mind in selecting the most fitting treatment for her.” For Susan Bakken of Denver, Colorado, Oncotype DX provided a different kind of peace of mind. Susan’s Recurrence Score indicated that she was at high risk of cancer recurrence, and would likely benefit significantly from chemotherapy-to both her surprise and her doctor’s. “Based on the other tests I had, my doctor said he wouldn’t have otherwise recommended chemotherapy. I was shocked to find out my result, but I was so glad I did because I believe this test basically saved my life,” explained Susan. Elizabeth Sloan is also grateful for the information she gained from Oncotype DX. “Not all cancers are the same, so why treat everyone the same way with something so toxic?” she said. “It’s so remarkable that finally, doctors can distinguish one person’s cancer from another-I’m just so thankful.” Oncotype DX is a simple test that can only be ordered by a physician. It is performed on a small amount of breast tumor tissue removed during a standard lumpectomy, mastectomy or biopsy, meaning no additional procedure is required.
? ॐ सह नाववतु । सह नौ भुनक्तु । सह वीर्यं करवावहै । तेजस्वि नावधीतमस्तु मा विद्विषावहै । ॐ शान्तिः शान्तिः शान्तिः ॥ अर्थ :'' हे! परमेश्वर ,हम शिष्य और आचार्य दोनों की साथ-साथ रक्षा करें। हम दोनों (गुरू और शिष्य) को साथ-साथ विद्या के फल का भोग कराए। हम दोनों एकसाथ मिलकर विद्या प्राप्ति का सामर्थ्य प्राप्त करें। हम दोनों का पढ़ा हुआ तेजस्वी हो। हम दोनों परस्पर द्वेष न करें''। ''सौंदर्य लहरी''की महिमा ;- 17 FACTS;- 1-सौंदर्य लहरी (संस्कृत: सौन्दरयलहरी) जिसका अर्थ है “सौंदर्य की लहरें” ऋषि आदि शंकर द्वारा लिखित संस्कृत में एक प्रसिद्ध साहित्यिक कृति है। कुछ लोगों का मानना है कि पहला भाग “आनंद लहरी” मेरु पर्वत पर स्वयं गणेश (या पुष्पदंत द्वारा) द्वारा उकेरा गया था। शंकर के शिक्षक गोविंद भगवदपाद के शिक्षक ऋषि गौड़पाद ने पुष्पदंत के लेखन को याद किया जिसे आदि शंकराचार्य तक ले जाया गया था। इसके एक सौ तीन श्लोक (छंद) शिव की पत्नी देवी पार्वती / दक्षिणायनी की सुंदरता, कृपा और उदारता की प्रशंसा करते हैं।सौन्दर्यलहरी/शाब्दिक अर्थ सौन्दर्य का
टिप्पणियाँ
एक टिप्पणी भेजें
vigyan ke naye samachar ke liye dekhe